{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'hemophilia A and B adult male patients with moderate or severe hemophilia. The study was', 'conducted in 4 parts:', 'Part A (N=4): randomized, placebo-controlled, single-blind single-ascending dose', '(SAD) phase in healthy subjects (0.03 mg/kg SC single dose)', 'Part B (N=12): open-label, multiple-ascending dose (MAD) phase in patients with', 'moderate to severe hemophilia A or B without inhibitors (0.015 to 0.075 mg/kg SC once', 'weekly)', 'Part C (N=18): open-label, exploratory multiple dose (MD) phase in patients with', 'moderate to severe hemophilia A or B without inhibitors (0.225 to 1.8 mg/kg or 80 mg', 'fixed dose SC once monthly)', 'Part D (N=17): open-label MD phase in patients with moderate to severe hemophilia A', 'or B with inhibitors (50 or 80 mg fixed dose SC once monthly)', 'Study ALN-AT3SC-001 was completed on 20 July 2017 (last patient last visit).', 'Study ALN-AT3SC-002 is a Phase 1/2 multicenter, multinational, open-label extension study to', 'evaluate the long-term safety and efficacy of fitusiran in male patients with moderate or severe', 'hemophilia A or B, with or without inhibitors, who previously tolerated dosing in Study', 'ALN-AT3SC-001. Study ALN-AT3SC-002 is currently ongoing. A total of 34 patients who', 'previously participated in Study ALN-AT3SC-001 and received at least 1 dose of SC fitusiran', 'ranging from 0.225 to 1.8 mg/kg or 50 mg or 80 mg fixed doses have enrolled in the extension', 'study. These 34 patients include 19 non-inhibitor patients (14 with hemophilia A and 5 with', 'hemophilia B) and 15 inhibitor patients (13 with hemophilia A and 2 with hemophilia B). Three', 'patients began the extension study on weight-based doses (0.225, 0.9 or 1.8 mg/kg) reflecting', 'their original Phase 1 dose. All patients were transitioned to either 50 mg monthly (N=13) or', '80 mg monthly (N=21) after no more than 4 doses. Patients are currently receiving either 50 mg', '(N=13) or 80 mg (N=21) fixed doses in this extension study, which is ongoing.', 'For a more complete summary and the most recent available pharmacokinetic,', \"pharmacodynamic, safety and efficacy data see the Investigator's Brochure.\", '1.2.2.1.', 'Summary of Efficacy', 'Preliminary efficacy for pooled ALN-AT3SC-001 and ALN-AT3SC-002 data include analysis of', 'annualized bleeding rate (ABR). For the purpose of ABR calculation, fitusiran \"Onset Period\"', 'and an \"Efficacy Period\" were defined. The Onset Period was defined as the first 28 days after', 'the first dose of fitusiran, during which the target pharmacodynamic effect is reached. The', 'Efficacy Period, during which bleeds were counted for the purpose of ABR calculation, was', 'defined as starting on Day 29. For patients who did not have an interruption in treatment', '>56 days between the Phase 1 study (ALN-AT3SC-001) and this Phase 1/2 extension study', '(ALN-AT3SC-002), bleed data from ALN-AT3SC-001 were included and the Efficacy Period', 'was defined as starting on Day 29 of that study. As of 8 August 2017, 33 of 34 patients enrolled', 'in the extension study met criteria for inclusion in this analysis, with one patient not yet having', 'completed 28 days on study.', 'Patients entering the extension study all received fitusiran as a once monthly injection. Initial', 'doses ranged from 0.225 mg/kg to 1.8 mg/kg in 3 patients, but all patients were transitioned to', 'either 50 mg (N=13) or 80 mg (N=21) fixed doses after <4 doses. No prophylactic use of factor', 'Property of the Sanofi Group - strictly confidential', '29']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'concentrates or BPAs were allowed after the first dose of fitusiran, with only on-demand use of', 'these agents for the treatment of any breakthrough bleeding events.', 'The ABR was determined for non-inhibitor and inhibitor patients receiving 50 mg or 80 mg.', 'The prestudy ABR was reported at ALN-AT3SC-001 study entry, prior to beginning treatment', 'with fitusiran. The ABR of patients from combined data from studies ALN-AT3SC-001 and', 'ALN-AT3SC-002 reflects efficacy across hemophilia subtypes in both inhibitor and', 'non-inhibitor patients. In patients on 80 mg monthly, the dose selected for Phase 3 studies, the', 'median ABR during the Efficacy Period (Day 29 to the data cut-off [8 August 2017]) is 1.46 and', '0 in non-inhibitor (N=9) and inhibitor (N=11) patients, respectively. The median ABR on 50 mg', 'monthly was 1.57 for non-inhibitor (N=10) and 6.84 for inhibitor (N=3) patients. All of the', 'non-inhibitor patients on prophylactic therapy (N=7) pre-study either maintained low ABR, or', 'demonstrated improved ABR on fitusiran, and the median ABR for this group was 1.7.', 'A complete summary of available clinical efficacy data relevant to fitusiran is presented in the', \"Investigator's Brochure.\", '1.2.2.2.', 'Summary of Safety', 'As of 31 August 2017, 42 male patients with severe or moderate hemophilia A or B, with or', 'without inhibitors, have received fitusiran in clinical studies. Single and multiple doses of', 'fitusiran have been generally well tolerated. Most patients have reported at least 1 AE, the', 'majority of which were assessed as mild or moderate in intensity and unrelated to investigational', 'medicinal product (IMP). The most common AEs reported were injection site reactions, which', 'were all mild and generally transient.', 'Elevations of liver transaminases occurred in 13 of 42 patients dosed with fitusiran. None of the', 'liver transaminase elevations were associated with elevations of total serum bilirubin >2 X the', 'upper limit of normal (ULN). Except in one patient, these elevations were asymptomatic, and', 'occurred in patients with a documented history of prior HCV infection.', 'Eleven of 42 patients reported a total of 14 SAEs. Out of these, 3 SAEs (elevated alanine', 'aminotransferase [ALT] and aspartate aminotransferase [AST], seizures, and cerebral venous', 'sinus thrombosis [CVST]) were assessed as possibly related to fitusiran.', 'Two patients discontinued fitusiran due to AEs (1 due to a non-serious AE of non-cardiac chest', 'pain and another due to SAEs of elevated ALT and AST.', 'One death has been reported in a patient with CVST in ALN-AT3SC-002, which was considered', 'possibly related to fitusiran. This occurred in a 27-year old patient who had been on study for', '15 months. The patient was hospitalized for headache several days after treating hip pain with', '31 IU/kg to 46 IU/kg factor VIII. While the patient was initially suspected of having viral', 'meningitis, he was subsequently diagnosed with subarachnoid hemorrhage on the basis of', 'computed tomography (CT) imaging, and treated with full dose Factor VIII concentrate two to', \"three times daily. Over a 14-day hospitalization, the patient's medical condition worsened\", 'despite the administration of FVIII concentrate and he died from subsequent cerebral edema.', 'Post mortem review of images by independent neuro-radiologists confirmed that the initiating', 'event was a CVST, and not a subarachnoid hemorrhage. The event is thus categorized as', 'possibly related to fitusiran. No other thromboembolic events have been observed.', 'Property of the Sanofi Group - strictly confidential', '30']\n\n###\n\n", "completion": "END"}